Beta Lactam Summary Table Flashcards
Clinical application:
Streptococcal infections, meningococcal infections, neurosyphilis
Penicillin G
Clinical application:
Skin and soft tissue infections, UTI, surgical prophylaxis
Cefazolin (1st gen cephalosporin)
Clinical application:
Serious infections such as pneumonia and serpsis
Imipenem-cilastatin
Infections caused by aerobic, gram-negative bacteria in patients with immediate hypersensitivity to penicillins
Aztreonam
Clinical applcations:
Infections caused by gram-positive bacteria including sepsis, endocarditis and meningitis
C difficile colitis (oral formulation)
Vancomycin
Clinical application:
Infections caused by gram-positive bacteria including sepsis and endocarditis
Daptomycin
HL of penicillin G and dosing interval
30min HL
every 4hrs
toxicity of penicillin G
immediate hypersensitivity, rash, seizures
toxicity of cefazolin
rash, drug fever
HL and dosing interval of cefazolin
HL 1.5 given every 8hrs
route of administration of cefazolin
IV
Route of administration of penicillin G
IV
route of administration of imipenem-cilastatin
IV
cilastatin is added to prevent??
hyrolysis by renal dehydropeptidase
HL and dosing interval or imipenen-cilastatin
HL 1
every 6-8 hrs
toxicity of imipenem-cilastatin
seizures especially in renal failure or with high doses
route of administration of aztronam
IV
HL and dosing interval of aztreonam
HL 1.5
dosing interval 8hrs
route of administration of vancomycin
oral
Hl of vancomycin
6hrs
toxicity of vancomycin
“red man syndrome”
nephrotoxicity
route of administration of daptomycin
IV
HL of daptomycin
8hrs
once a day
inactivated by pulmonary surfactant so cannot be used to treat pneumonia
daptomycin
toxicity of daptomycin
myopathy
intramuscular and long acting formulations of penicillins
benzathine penicillin
procaine penicillin
IV penicillins added stability to staphylococcal B-lactamase
nafcillin and oxacillin
clearance of nafcillin and oxacillin
biliary clearance
penicillins that has greater activity versus gram-negative bacteria; addition of B-lactamase inhibitors restores activity against many B-lactamses-producing bacteria
ampicillin,amoxicillin, piperacillin
GLYCOPEPTIDE.
IV, similar to vancomycin except long half life ( 45 - 70h ) permits once-daily dosing
teicoplanin
GLYCOPEPTIDE
IV, 10days HL, permits once-weekly dosing
dalbavancin and oritavancin
GLYCOPEPTIDE
IV, once-daily dosing
Telavancin
MOA
prevents bacterial cell wall synthesis by binding to and inhibitng cell wall transpeptidases
penicillins
cephalosporins
carbapenems
monobactams
MOA
inhibits cell wall synthesis by binding to the D-ala-D-ala terminus of nascent peptidoglycan
glycopeptide (vancomycin)
MOA
binds to cell membrane, causing depolarization and rapid cell death
lipopeptide (daptomycin)
effects
rapid bactericidal activity against susceptible bacteria
penicillin
cephalosporins
carbapenems
monobactams
effects
bactericidal activity against susceptible bacteria, slower kill than B-lactam antibiotics
glycopeptide (vancomycin)
bactericidal activity against susceptible bacteria - more rapidly bactericidal than vancomycin
lipopeptide (daptomycin)
IV, similar to imipenem; stable to renal dehydropeptidase, lower incidence of seizure
meropenem, doripenem
IV, longer HL allows for once-daily dosing, lacks activity versus pseudomonas aeruginosa and acinetobacter
ertapenem
oral and IV, 2nd gen drug, improved activity vs pneumococcus and haemophilus influenzae
cefuroxime
IV, 2nd gen drug, activity versus bacteriodes fragilis allows for use in abdominal, pelvic infections
cefotaten, cefoxitin
IV, third gen drug, good CNS penetration, many uses including pneumonia, meningitis, pyelonephritis and gonorrhea
ceftriaxone
HL of ceftriaxone (3rd gen)
6 hrs
IV, 3rd gen, similar to cefriaxone; renal clearance and HL of 1hr
cefotaxime
IV, 3rd gen, poor gram-positive activity, good activity versus pseudomonas aeruginosa
ceftazidime
IV, 4th gen drug, braod activity with improved stability to chromosal B-lactamases
cefepime
active against methicillin-resistant staphylococci, broad gram-negative activity not including pseudomanas aeruginosa
ceftaroline
IV, cephalosporin-B-lactamase inhibitor combination drugs, broad activity with improved stability to chromosomal B-lactamase and some extended spectrum B-lactamases
ceftazidine-avibactam
ceftolozane-tazobactam